Approximately 65 patients will be entered into this study taking place in North America. The aim of this study is to evaluate the safety, efficacy and absorption of an investigational drug in patients with C. difficile-associated diarrhea (CDAD). All study related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is 6 weeks.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
65
Unnamed facility
Modesto, California, United States
Unnamed facility
Honolulu, Hawaii, United States
Unnamed facility
Maywood, Illinois, United States
Unnamed facility
Baltimore, Maryland, United States
Unnamed facility
Worcester, Massachusetts, United States
Unnamed facility
West Bloomfield, Michigan, United States
Unnamed facility
Butte, Montana, United States
Unnamed facility
Cedar Knolls, New Jersey, United States
Unnamed facility
Neptune City, New Jersey, United States
Unnamed facility
Syracuse, New York, United States
...and 3 more locations
Clinical Success
Safety
The extent of tolevamer absorption
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.